- Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
For: Gastric Neoplasms · Gastroesophageal Adenocarcinoma · Esophageal AdenocarcinomaArgentina · Australia · Belgium - Active not recruitingPHASE3
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
This study looks at treating muscle-invasive bladder cancer. It compares standard chemotherapy with chemotherapy plus a new immunotherapy drug called nivolumab, given before and after surgery. The aim is to see if adding nivolumab helps more people.
For: Urinary Bladder Neoplasms · Muscle-Invasive Bladder CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This study looks at a new combination of drugs, adagrasib, pembrolizumab, and chemotherapy, for people with a specific type of advanced non-small cell lung cancer (NSCLC) that hasn't been treated before and has a KRAS G12C gene change.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
The CompARE trial is testing new treatments for a type of throat cancer called oropharyngeal cancer. It compares different ways of using radiotherapy, surgery, and immunotherapy to see if they improve survival and quality of life for adults with more advanced forms of this cancer.
For: Oropharyngeal CancerIreland · United Kingdom - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This study aims to see if adding the drug pembrolizumab to standard chemotherapy before and after surgery helps people with early-stage non-small cell lung cancer live longer and prevent the cancer from returning. It's a large study comparing this new approach with chemotherapy alone.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
For: Endometrial Cancer · Gastric Cancer · Metastatic Castration-resistant Prostate CancerUnited States · Canada · China - Active not recruitingPHASE3
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
This study looks at new drug combinations for advanced bladder cancer that hasn't been treated before. It compares them to standard chemotherapy to see if they're safer and work better.
For: Urothelial CancerUnited States · Australia · Austria - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
This study is looking at new ways to treat advanced non-small cell lung cancer (a type of lung cancer) that has spread. It compares an experimental drug, rilvegostomig, with a standard drug, pembrolizumab, both given with chemotherapy, to see which works better and is safer.
For: Non-squamous Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer
This study looks into adding a short course of chemotherapy (Paclitaxel and Carboplatin) before standard chemoradiation for women with locally advanced cervical cancer. The aim is to see if this extra step improves how long women live and if the cancer stays away.
For: Cervical CancerBrazil · India · Italy - Active not recruitingPHASE3
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
This study looks at the best way to treat penile cancer that has spread to nearby lymph nodes. It compares surgery alone with surgery after chemotherapy or chemoradiotherapy. It also checks if extra surgery in the pelvis helps prevent cancer from coming back.
For: Squamous Cell Carcinoma of the Penis, Usual TypeUnited States · United Kingdom - RecruitingPHASE1, PHASE2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
This study looks at new drug combinations for advanced lung cancer. It combines telisotuzumab adizutecan with immune-boosting drugs like budigalimab or pembrolizumab. The goal is to find safe and effective doses to help people with non-small cell lung cancer who haven't had prior treatment for advanced disease.
For: Non Small Cell Lung CarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
This study is looking at a new treatment for early-stage lung cancer that can be removed with surgery. It combines standard chemotherapy with a newer drug called nivolumab. Researchers want to see if this combination helps people live longer without their cancer returning.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
This study is testing a new cancer medicine, GEN1042, both by itself and with other treatments. It's for people with certain advanced solid tumours where standard treatments haven't worked or aren't available. The main goals are to check its safety and see how well it fights cancer.
For: Malignant Solid Tumor · Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC)United States · Denmark · France - Active not recruitingPHASE3
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
This study looks at new ways to treat advanced lung cancer that can't be removed by surgery. It combines standard chemotherapy and radiation with newer drugs, pembrolizumab and olaparib, to see if they can improve survival compared to current treatments.
For: Lung Neoplasms · Carcinoma, Non-Small-Cell LungUnited States · Argentina · Canada - RecruitingPHASE1
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
This study is looking into a new treatment called KRC-01 for cervical cancer. It aims to see if KRC-01 is safe, if patients can tolerate it, and if it helps shrink tumours when used with standard treatments like radiotherapy and chemotherapy.
For: Cervical CancerIndia · Thailand · United Kingdom - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
This study tested new drug combinations for advanced oesophageal cancer. It looked at pembrolizumab with lenvatinib and chemotherapy, versus pembrolizumab and chemotherapy, to see which worked best and was safest. The study has now stopped, with no safety concerns being the reason.
For: Metastatic Esophageal Squamous Cell CarcinomaUnited States · Argentina · Canada - RecruitingPHASE1, PHASE2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
This study looks at a new drug, sacituzumab tirumotecan, alone or with other common treatments for advanced bowel, pancreatic, and bile duct cancers. Researchers want to see if it's safe, tolerable, and can shrink these cancers.
For: Colorectal Cancer · Pancreatic Ductal Adenocarcinoma · Biliary Tract CancerUnited States · Australia · Canada - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
This study is for women with cervical cancer that has spread. It's testing new combinations of medicines (sac-TMT, pembrolizumab, and possibly bevacizumab) to see if they are safe and can help people live longer or stop their cancer from getting worse.
For: Cervical CancerUnited States · Argentina · Austria - Active not recruitingPHASE3
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
This study compares two chemotherapy treatments for germ cell tumours that have returned or didn't respond to previous treatment. It looks at a standard chemotherapy plan versus a stronger plan with a stem cell transplant to see which works better.
For: Germ Cell Tumor · Teratoma · ChoriocarcinomaUnited States · Australia · Belgium - RecruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
This study looks at new drug combinations for a specific type of advanced lung cancer. It compares a new drug, Divarasib, with Pembrolizumab, against standard treatments to see which works best and is safest for patients with KRAS G12C-mutated non-small cell lung cancer.
For: Non-Small Cell Lung Cancer · KRAS G12C Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
This study looks at new ways to treat a type of lung cancer before surgery. We're testing a drug called osimertinib, either alone or with chemotherapy, against chemotherapy by itself. The goal is to see if these new treatments can help more people with resectable non-small cell lung cancer.
For: Non-Small Cell Lung CancerUnited States · Austria · Brazil - RecruitingPHASE3
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
This study looks at new ways to treat a serious childhood cancer called neuroblastoma. It tests different treatment combinations, including chemotherapy and immunotherapy, to find the best approach for children with high-risk forms of the disease. The aim is to improve their chances of getting better.
For: NeuroblastomaAustralia · Austria · Belgium - RecruitingPHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
This study looks at new drug combinations for stomach (gastric) or food pipe (GEJ) cancer that has a specific marker called HER2. It compares different treatment mixes to see which works best and is safest for advanced cancer.
For: HER2-positive Gastric Cancer · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
This study is looking at a new treatment called pembrolizumab for advanced or recurrent womb cancer that has a specific genetic marker. It compares this new treatment to standard chemotherapy to see which works better and is safer for women who haven't had chemotherapy for this stage of cancer before.
For: Endometrial NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
This study looks at a new drug, pembrolizumab, for certain types of oesophageal cancer. It compares giving pembrolizumab alongside standard chemotherapy and radiotherapy with giving a dummy drug (placebo) with the same standard treatment. We want to see if the new drug can help people live longer or prevent the cancer from coming back.
For: Esophageal Squamous Cell Carcinoma (ESCC) · Gastroesophageal Junction Carcinoma (GEJC) · Esophageal Adenocarcinoma (EAC)United States · Argentina · Belgium - RecruitingPHASE3
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
This study looks at a new way to give chemotherapy for a type of cancer called germ cell tumour. We're comparing a faster treatment schedule (accelerated BEP) with the usual one, to see if it works better for people with more serious forms of the disease.
For: Germ Cell TumorUnited States · Australia · New Zealand - Active not recruitingPHASE2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
This study looks at new ways to treat bladder cancer that has spread or can't be removed with surgery. It's testing a drug called sacituzumab govitecan, sometimes on its own, and sometimes with other new treatments, to see if they are safe and effective.
For: Metastatic Urothelial CancerUnited States · France · Germany - Active not recruitingPHASE3
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
This study is looking at how well two new drugs, enfortumab vedotin and pembrolizumab, work together to treat advanced bladder cancer that has spread. It compares them to standard chemotherapy treatments to see if they are a better option.
For: Urothelial CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study looks at a new drug, zongertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares zongertinib to standard treatment to see if it can better slow down cancer growth and improve how long people live without their cancer getting worse.
For: Lung Cancer, Non-squamous, Non-small CellUnited States · Argentina · Australia - Active not recruitingPHASE3
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This study compares a new treatment, Atezolizumab, to standard care for patients with early-stage lung cancer after surgery and chemotherapy. It aims to see if Atezolizumab can prevent the cancer from returning and help people live longer.
For: Non-Small Cell Lung CancerUnited States · Australia · Belgium - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
For: Metastatic Non-small Cell Lung Cancer With MTAP DeletionUnited States · Argentina · Australia - RecruitingPHASE2, PHASE3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
This study is for people with a type of lung cancer that has a specific gene change (EGFR mutation) and has not responded to previous treatment. It compares a new medicine called Iza-bren with standard chemotherapy (carboplatin or cisplatin plus pemetrexed) to see which works better.
For: Non-Small Cell Lung CancerUnited States · Argentina · Belgium - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
For: Non Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
For: Non-small Cell Lung CancerUnited States · Argentina · Austria - Active not recruitingPHASE3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This study is testing a new combination of treatments for adults with advanced lung cancer (NSCLC) that hasn't spread to the brain or spine and doesn't have certain genetic changes. It compares this new treatment to a standard one, hoping it works better.
For: NSCLCUnited States · Austria · Brazil - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
This study is looking at a new treatment for head and neck cancer that has come back or spread. It combines a new drug, amivantamab, with standard treatments to see if it works better than standard care alone to fight the cancer.
For: Squamous Cell Carcinoma of Head and NeckUnited States · Australia · Austria - RecruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
This study looks at new treatments for a type of womb cancer that has spread or returned. It compares a new drug combination (sac-TMT with pembrolizumab) against pembrolizumab alone to see if it helps patients live longer and keeps the cancer from growing.
For: Endometrial CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
For: Gastric CancerUnited States · Brazil · Canada - RecruitingPHASE3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
This study looks at a new treatment called intismeran autogene, given with pembrolizumab, after surgery for non-small cell lung cancer. We want to see if this combination stops the cancer from coming back compared to pembrolizumab alone.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - RecruitingPHASE3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
This study looks at how best to treat a type of cancer called germ cell tumours in children and adults. It compares simply watching the tumour after surgery with different chemotherapy treatments to see which works best and causes fewer side effects.
For: Childhood Extracranial Germ Cell Tumor · Extragonadal Embryonal Carcinoma · Germ Cell TumorUnited States · Australia · Canada - Active not recruitingPHASE3
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study looked at new ways to treat a type of lung cancer called extensive-stage small cell lung cancer (ES-SCLC). It compared a combination of medicines with standard chemotherapy to see if it could help people live longer. The study was changed partway through, so the focus shifted.
For: Small Cell Lung CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
For: Hepatocellular Carcinoma · Biliary Tract CancerUnited States · China · Hong Kong - RecruitingPHASE1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.
For: Carcinoma, Non-Small Cell Lung · Squamous Cell Carcinoma of Head and Neck · HER2 Negative Breast NeoplasmsUnited States · France · South Korea - RecruitingPHASE1, PHASE2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
This study looks at a new drug, Divarasib, for advanced lung cancer with a specific gene change (KRAS G12C). It checks if the drug is safe, how it works, and if it can shrink tumours, either alone or with other cancer treatments.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
This study compares a new drug, TAK-788, with standard chemotherapy for advanced lung cancer (NSCLC) where the cancer has a specific genetic change (EGFR exon 20 insertion mutation). It's for people who haven't had prior treatment for their advanced cancer.
For: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)United States · Australia · Austria - RecruitingPHASE3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study looks at a new way to give a cancer drug called tislelizumab for advanced stomach cancer. We're comparing injections under the skin to drips into a vein, alongside usual chemotherapy. We want to see if the injection works just as well and is easier for patients.
For: Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Austria - RecruitingPHASE3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
This study is looking at new treatments for advanced bile duct cancer that has a specific marker called HER2. We want to see if these new medicines work better and are safer than standard treatments for patients who haven't had treatment for their advanced cancer before.
For: Biliary Tract CancerUnited States · Australia · Austria - RecruitingPHASE3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
This study is testing a new drug called Zanidatamab for people with advanced HER2-positive biliary tract cancer. It compares this new drug combined with standard treatments to standard treatments alone, to see if it's more effective and safe.
For: Biliary Tract CancerUnited States · Argentina · Belgium